Browsing: Gynecological

The phase III PARCER trial randomized 300 postoperative cervical cancer patients to IG-IMRT versus 3DCRT (50 Gy/25 fx ± weekly…

In one of the world’s lowest-fertility countries, reproductive risk factors for ovarian cancer are shifting across generations. A nationwide cohort…

Population-based data of all women undergoing hysterectomy or tubal permanent contraception in British Columbia between 2008 and 2020, opportunistic bilateral…

We now know that there are distinct molecular classes of endometrial cancer with very different risks of recurrence. PORTEC 4a…

Top Line: Hypofractionation is an attractive means to shorten overall treatment time for locally-advanced cervical cancer.The Study: An Indian single-arm…

Nimotuzumab added to image-guided RT delivered strikingly high response rates and 2-year DFS of 85% in elderly patients with locally…

The phase 3 PHENIX trial randomized 838 women with stage IA1–IIA1 cervical cancer and negative intraoperative sentinel nodes to either…

Top Line: Does adding concurrent cisplatin to post-op radiation improve outcomes for intermediate-risk cervical cancer after hysterectomy?The Study: Adjuvant therapy…

Top Line: Does ultrasensitive circulating tumor DNA (ctDNA) predict who may be headed for trouble after chemoradiation for locally advanced…

Top Line: What are the long-term outcomes of PORTEC-3 based on molecular classification? The Study: PORTEC-3 was a phase 3…